Bio Pharma Dive
FEBRUARY 16, 2022
Study results indicate the company's fast-acting medicine may help patients already on existing drugs. But its limited effects may curb its potential, Wall Street analysts said.
World of DTC Marketing
FEBRUARY 16, 2022
COVID may be winding down, but the damage is done in deaths and long COVID. We don’t understand much, but we do know that there is a correlation between COVID severity and obesity/diabetes. The question thus becomes, “will the medical community finally address the obesity epidemic, or will we continue to do nothing essentially?” Obesity turned out to be a significant risk factor for covid hospitalization and death, especially non-elderly.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
FEBRUARY 16, 2022
Natalie Holles was named as head of the Atlas-backed startup last year after leaving gene therapy developer Audentes following its acquisition by Astellas.
BioPharma Reporter
FEBRUARY 16, 2022
A number of intranasal vaccines against COVID-19 are in development: hoping to provide a point of difference against authorized vaccines but also create a springboard for wider development against other respiratory diseases.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Bio Pharma Dive
FEBRUARY 16, 2022
Star Therapeutics has an unusual hub-and-spoke model that it believes will make rare disease research more efficient. Its first company was unveiled Wednesday, and CEO Adam Rosenthal says another is waiting in the wings.
BioPharma Reporter
FEBRUARY 16, 2022
Lipid nanoparticle systems (LNPs) as a delivery mechanism for novel drug modalities are proving effective, but there are bioanalytical challenges associated with encapsulation, says an expert.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
pharmaphorum
FEBRUARY 16, 2022
AstraZeneca’s Saphnelo has become the first new drug to be approved to treat the autoimmune disease systemic lupus erythematosus (SLE) in the EU for more than 10 years. The European Commission has cleared the type I interferon receptor antagonist antibody as an add-on therapy to standard treatment for adults with moderate to severe SLE, four years after a miss in a phase 3 trial put the future of the drug in doubt.
XTalks
FEBRUARY 16, 2022
The globalization of the food chain has resulted in increased complexity and digital activity, meaning more opportunities for food fraud to occur. Since the COVID-19 pandemic forced many grocery stores, quick-service restaurants (QSRs) and other food industry players to pivot to digital technologies including mobile apps and contactless payment methods, food fraud has been prevalent in recent years.
Scienmag
FEBRUARY 16, 2022
University of Houston researchers have received $4.4 million from the U.S. Department of Energy’s Advanced Research Projects Agency-Energy (ARPA-E) for two projects developed in the Cullen College of Engineering and Texas Center for Superconductivity at the University of Houston (TcSUH). Credit: University of Houston University of Houston researchers have received $4.4 million from the U.S. […].
Pharma Times
FEBRUARY 16, 2022
Saphnelo is the first therapy in over a decade for patients with moderate to severe systemic lupus erythematosus
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Scienmag
FEBRUARY 16, 2022
The Council for the Advancement of Science Writing (CASW) is now accepting entries for the new Sharon Begley Science Reporting Award. The deadline is April 30, 2022. Credit: Courtesy Edward Groth, III The Council for the Advancement of Science Writing (CASW) is now accepting entries for the new Sharon Begley Science Reporting Award. The deadline […].
BioPharma Reporter
FEBRUARY 16, 2022
Multiple pharma R&D teams are seeking to transform how diabetes treatment is managed.
Scienmag
FEBRUARY 16, 2022
Peer-reviewed/Modelling Study/People Credit: The Lancet Peer-reviewed/Modelling Study/People Largest study to present internationally comparable estimates of the prevalence of sexual and/or physical violence against women by a male intimate partner. Estimates from a global database of surveys conducted between 2000 and 2018 indicate that 27% of women aged 15-49 have experienced physical and/or sexual intimate partner […].
BioPharma Reporter
FEBRUARY 16, 2022
From wearable injectors to nasal inhalation devices, experts expect to see many developments in drug delivery as the biologics industry grows.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Scienmag
FEBRUARY 16, 2022
Germany in the year 2050. The goal of a carbon dioxide-neutral life and economy has been achieved: Greenhouse gas emissions have fallen drastically, and unavoidable emissions are counterbalanced. Changes in energy supply and new solutions in industry, transportation and traffic are key to avoiding and reducing emissions. Adaptations in agriculture and land management, such as […].
Pharma Times
FEBRUARY 16, 2022
Rare Disease Day has inspired a pioneering video to support patients living with rare conditions
Scienmag
FEBRUARY 16, 2022
The Salton Sea geothermal field in California potentially holds enough lithium to meet all of America’s domestic battery needs, with even enough left over to export some of it. But how much of that lithium can be extracted in a sustainable and environmentally friendly way? And how long will the resource last? These are just […].
pharmaphorum
FEBRUARY 16, 2022
A woman with HIV who received a stem cell transplant to treat acute myeloid leukaemia (AML) appears to have been cured of the infection according to US researchers. The case study described at the Conference on Retroviruses and Opportunistic Infections (CROI) this week involved a mixed-race woman who had been on antiretroviral therapy (ART) for four years before being diagnosed with AML.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Scienmag
FEBRUARY 16, 2022
Microplastics increase the toxicity of organic pollutants in the environment Credit: Tel Aviv University Microplastics increase the toxicity of organic pollutants in the environment by a factor of 10 The study suggests that increased toxicity may cause severe damage to the digestive system and to human health The researchers stated: “Microplastics are a kind of […].
Drug Patent Watch
FEBRUARY 16, 2022
Annual Drug Patent Expirations for PREVACID+IV Prevacid Iv is a drug marketed by Takeda Pharms Na and is included in one NDA. There is one patent protecting this drug. The…. The post New patent expiration for Takeda Pharms drug PREVACID IV appeared first on DrugPatentWatch - Make Better Decisions.
Scienmag
FEBRUARY 16, 2022
A scientist at Osaka City University has discovered skyrmions with half-integer topological numbers in a ferromagnetic superfluid. Credit: Hiromitsu Takeuchi A scientist at Osaka City University has discovered skyrmions with half-integer topological numbers in a ferromagnetic superfluid. “This may bring about a major change in the long history of research on skyrmions,” states Hiromitsu Takeuchi, […].
Drug Patent Watch
FEBRUARY 16, 2022
Annual Drug Patent Expirations for CYSVIEW+KIT Cysview Kit is a drug marketed by Photocure Asa and is included in one NDA. It is available from one supplier. There is one…. The post New patent for Photocure Asa drug CYSVIEW KIT appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Scienmag
FEBRUARY 16, 2022
When Charles Darwin first codified the theory of evolution by means of natural selection, he thought of it as a gradual process. “We see nothing of these slow changes in progress, until the hand of time has marked the long lapse of ages,” he wrote in his seminal work, “On the Origin of Species.” Credit: […].
Drug Patent Watch
FEBRUARY 16, 2022
Annual Drug Patent Expirations for GIVLAARI Givlaari is a drug marketed by Alnylam Pharms Inc and is included in one NDA. There are twelve patents protecting this drug. This drug…. The post New patent for Alnylam Pharms drug GIVLAARI appeared first on DrugPatentWatch - Make Better Decisions.
Scienmag
FEBRUARY 16, 2022
There is a broad consensus that some people have stronger social and financial incentives to commit crimes than others do. Yet, people who face the same incentives can also make different choices because they have different preferences. This means that they weigh the costs and benefits of committing a criminal action differently. Credit: Center for […].
Drug Patent Watch
FEBRUARY 16, 2022
Annual Drug Patent Expirations for VIBERZI Viberzi is a drug marketed by Allergan Holdings and is included in one NDA. It is available from one supplier. There are seventeen patents…. The post New patent for Allergan Holdings drug VIBERZI appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Scienmag
FEBRUARY 16, 2022
Researchers of the University of Barcelona and the August Pi i Sunyer Biomedical Research Institute (IDIBAPS) have shown in a study with lung cancer cell lines that the same molecular signals that control the embryonic development can also control the harmfulness of cancer cells. The results of the study, published in the Journal of Experimental […].
XTalks
FEBRUARY 16, 2022
In this episode, Ayesha discussed the NHS’s recommendation of Libmeldy, a gene therapy for the treatment of the rare disease MLD, which is officially the world’s most expensive drug with a list price of almost $4 million USD. The drug was developed by Orchard Therapeutics and the NHS was able to negotiate a greater discount on it with the company so that it can offer it to patients in England.
Scienmag
FEBRUARY 16, 2022
In a new publication from Opto-Electronic Advances; DOI 10.29026/oea.2022.210036, authors from the Laser Engineering Group in the School of Engineering at the University of Liverpool, Liverpool, United Kingdom, discuss two-photon absorption and stimulated emission in poly-crystalline zinc selenide with femtosecond laser excitation. Credit: OEA In a new publication from Opto-Electronic Advances; DOI 10.29026/oea.2022.210036, authors from the Laser […].
pharmaphorum
FEBRUARY 16, 2022
Equillium has announced another bolt-on deal to expand its pipeline tripling the size of its clinical pipeline to three drug candidates via a $329 million agreement to acquire Bioniz Therapeutics. The La Jolla, California-based biotech licensed its first drug – itolizumab for graft-versus-host disease (GvHD), asthma and lupus nephritis – from Indian drugmaker Biocon in 2017.
Advertisement
The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. Demand-led supply and direct-to-patient distribution are next-generation solutions that are helping to meet these growing needs, allowing for more streamlined processes and patient-centric studies.
Expert insights. Personalized for you.
291 
Let's personalize your content